Dennis E. Kyle mostly deals with Plasmodium falciparum, Malaria, Pharmacology, Virology and Drug resistance. The Plasmodium falciparum study combines topics in areas such as Genetics, Chloroquine and Drug discovery. The study incorporates disciplines such as Internal medicine and Protozoa in addition to Malaria.
His studies deal with areas such as Artesunate, Artemisinin, Dihydroartemisinin and In vivo as well as Pharmacology. His Virology research is multidisciplinary, incorporating elements of Antibacterial agent, DHPS, Sulfadoxine/pyrimethamine, Sulfadoxine and Apicomplexa. His work on Halofantrine as part of general Mefloquine study is frequently connected to Resistance mutation, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
The scientist’s investigation covers issues in Plasmodium falciparum, Malaria, Pharmacology, Virology and Drug resistance. His Plasmodium falciparum research focuses on subjects like Chloroquine, which are linked to Verapamil. His work in Malaria addresses issues such as Drug discovery, which are connected to fields such as Naegleria fowleri and Microbiology.
His research in Pharmacology intersects with topics in Quinine, Artesunate and In vivo. His In vivo study incorporates themes from In vitro and Plasmodium berghei. As part of his studies on Virology, Dennis E. Kyle often connects relevant areas like Multiple drug resistance.
Microbiology, Malaria, Naegleria fowleri, Drug discovery and Virology are his primary areas of study. His research in Malaria focuses on subjects like Immune system, which are connected to Secretion. His study on Naegleria fowleri also encompasses disciplines like
His Virology research includes elements of Aquaporin 3, Parasitology, Plasmodium, Host and Plasmodium vivax. His Plasmodium vivax study is concerned with Plasmodium falciparum in general. Dennis E. Kyle merges Plasmodium falciparum with Geranylgeranyl pyrophosphate in his research.
Dennis E. Kyle mainly focuses on Malaria, Pharmacology, Plasmodium falciparum, Virology and Drug discovery. His work blends Malaria and Systematic evolution of ligands by exponential enrichment studies together. He interconnects Phenotype, Symptomatic relief, Parasitemia and Chemoprotective in the investigation of issues within Pharmacology.
The concepts of his Plasmodium falciparum study are interwoven with issues in Natural product, In vitro and In vivo. His study on Cryptosporidium parvum is often connected to LYSYL-tRNA SYNTHETASE as part of broader study in Virology. His Drug discovery study integrates concerns from other disciplines, such as Ion homeostasis, Parasite load, Immune system, Plasmodium vivax and Antibody.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Malaria: progress, perils, and prospects for eradication
Brian M. Greenwood;David A. Fidock;Dennis E. Kyle;Stefan H.I. Kappe.
Journal of Clinical Investigation (2008)
Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum.
S. J. Foote;D. E. Kyle;R. K. Martin;A. M. J. Oduola.
Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance
Donald J. Krogstad;Ilya Y. Gluzman;Dennis E. Kyle;Ayoade M. J. Oduola.
Evidence for the shikimate pathway in apicomplexan parasites
Fiona Roberts;Fiona Roberts;Craig W. Roberts;Jennifer J. Johnson;Dennis E. Kyle.
Clinical Studies of Atovaquone, Alone or in Combination with other Antimalarial Drugs, for Treatment of Acute Uncomplicated Malaria in Thailand
S Looareesuwan;C Viravan;H K Webster;D E Kyle.
American Journal of Tropical Medicine and Hygiene (1996)
Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand
Craig M. Wilson;Sarah K. Volkman;Sodsri Thaithong;Roger K. Martin.
Molecular and Biochemical Parasitology (1993)
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.
Wesley C. Van Voorhis;John H. Adams;Roberto Adelfio;Roberto Adelfio;Vida Ahyong.
PLOS Pathogens (2016)
A novel multiple-stage antimalarial agent that inhibits protein synthesis
Beatriz Baragaña;Irene Hallyburton;Marcus C. S. Lee;Marcus C. S. Lee;Neil R. Norcross.
Cardiac effects of antimalarial treatment with halofantrine
F. Nosten;F. O. Ter Kuile;C. Luxemburger;C. Woodrow.
The Lancet (1993)
Genetic Diversity of Plasmodium falciparum Histidine-Rich Protein 2 (PfHRP2) and Its Effect on the Performance of PfHRP2-Based Rapid Diagnostic Tests
Joanne Baker;James McCarthy;Michelle Gatton;Dennis E. Kyle.
The Journal of Infectious Diseases (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: